MEDIFAST INC

MEDIFAST INC

11.89
USD
-0.27
(-2.22%)
-2.32EPS
120.42MMarket Cap
Oct 26Next Earn
MEDIFAST INC
LSE:0K05
(London Stock Exchange)

Recent

price

11.89

P/E

ratio

- -

div

yld

0.13%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
18.29
21.35
23.22
23.53
22.52
22.81
23.18
25.29
41.94
60.63
79.42
130.38
142.79
98.5
55.12
35.13
28.73
Revenue per Share
1.39
1.33
1.16
1.74
1.04
1.68
1.51
2.32
4.67
6.62
8.74
14.01
12.82
9.13
0.19
-1.7
-2.32
Basic EPS, GAAP
1.19
1.45
2.34
2.25
1.46
2.22
1.9
3.35
4.68
6.3
11.83
5.15
15.89
12.97
1.56
0.11
0.36
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
1
1.29
1.94
3.01
4.52
5.46
6.4
6.71
0.07
0.02
0.02
Dividend per Share
4.66
4.73
6.59
7.5
6.66
7.51
8.09
9.07
9.19
8.91
13.36
17.47
14.26
18.49
19.21
18.1
17.56
Book Value per Share
4.59
4.67
6.56
7.5
6.66
7.51
8.09
9.07
9.19
8.91
13.36
17.47
14.26
18.49
19.21
18.1
17.56
Tangible Book Value per Share
14
14
14
14
13
12
12
12
12
12
12
12
11
11
11
11
11
Basic Weighted Avg Shares
258
298
319
324
285
273
275
302
501
714
935
1,526
1,599
1,072
602
386
317
Sales/Revenue/Turnover
12.28
9.18
8.52
11.85
10.6
10.52
9.78
13.14
13.78
12.76
14.35
14.17
11.56
11.79
0.48
-3.68
-6.15
Operating Margin (%)
6
8
8
8
8
7
5
4
4
5
4
7
11
13
13
14
14
Depreciation Expense
20
19
16
24
13
20
18
28
56
78
103
164
144
99
2
-19
-26
Net Income, GAAP
38.12
33.02
34.96
30.5
33.65
34.05
34.24
31.26
20.92
15.64
23.39
24.11
22
22.81
44.78
- -
- -
Effective Tax Rate (%)
7.61
6.22
4.98
7.4
4.62
7.35
6.5
9.19
11.14
10.92
11
10.75
8.98
9.27
0.35
-4.84
-8.08
Profit Margin (%)
45
44
60
65
55
63
77
88
85
75
123
137
82
132
150
159
160
Working Capital
5
4
4
- -
- -
- -
- -
- -
- -
10
7
26
20
16
10
6
22
LT Debt
72
73
91
98
80
89
96
109
109
105
157
202
155
201
210
199
196
Total Equity
29.7
23.46
20.01
26.98
21.89
21.96
19.09
26.55
49.89
66.92
70.66
80.3
67.64
46.24
0.68
- -
- -
Return on Invested Capital (%)
29.86
23.73
18.23
24.68
14.48
23.36
19.3
27.1
51.26
68.49
71.72
81.32
69.27
49.14
0.93
- -
- -
Return on Capital (%)
32.75
25.51
19.34
25.34
14.74
23.73
19.32
27.1
51.26
72.84
78.49
91.2
80.31
55.77
1.02
-9.13
-12.42
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
5
4
5
LT Borrowings
- -
- -
- -
LT Finance Leases
6
12
22
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
117
112
120

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
202
203
202
Cash, Cash Equivalents & STI
167
169
170
Accounts Receivable, Net
- -
- -
- -
Inventories
20
21
21
Total Current Liabilities
43
42
42
Payables & Accruals
38
38
36
ST Debt
5
4
5
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.23%
6.85%
-5.33%
Free Cash Flow
15.96%
-12.62%
-92.66%
Net Income, GAAP
-85.74%
-214.93%
-992.97%
Sales/Revenue/Turnover
10.54%
-8.94%
-35.96%
Total Cash Common Dividend
- -
-27.52%
-72.73%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
175
169
140
119
602
2025
116
106
89
75
386
2026
76
76
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.76
-0.75
0.1
0.07
0.19
2025
-0.07
0.23
-0.21
-1.65
-1.7
2026
-0.19
-0.28
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
- -
- -
- -
0.07
2025
0.02
- -
- -
- -
0.02
2026
0.01
0.01
- -
- -
- -
Business
Medifast, Inc. Medifast, Inc. (NYSE: MED) operates as a health and wellness company that develops, manufactures, and sells clinically proven nutrition products and coach-guided lifestyle programs primarily through its OPTAVIA brand; core offerings include portion-controlled meal replacements such as bars, shakes, soups, puddings, oatmeal, pancakes, smoothies, and soft bakes, alongside the 5 & 1 Plan featuring Lean & Green meals, the Habits of Health Transformational System, and specialized lines like OPTAVIA ACTIVE for muscle health with Essential Amino Acid Blends and whey protein, and OPTAVIA ASCEND high-protein mini meals and nutrient packs tailored for GLP-1 medication users and weight maintenance. Products reach customers via a network of independent OPTAVIA Coaches using direct sales, e-commerce, and community support, targeting consumers seeking weight management, metabolic health, and lifelong healthy habits in the United States weight management market. Founded in 1980 and headquartered in Baltimore, Maryland, the company conducts operations mainly in the U.S. with over 40 years of experience, subsidiaries including Optavia (formerly Take Shape for Life), Jason Pharmaceuticals, and recent innovations backed by a Scientific Advisory Board. Recent developments encompass the 2024 launch of OPTAVIA ASCEND to address gaps in GLP-1 support and muscle preservation, an ongoing collaboration with LifeMD providing coach clients access to clinicians and GLP-1 medications including joint marketing pilots, a planned 2025 program with new OPTAVIA ASCEND products and a clinical study on integrated nutrition-lifestyle outcomes, and optimized marketing spend reductions to $20-25 million for 2024 while enhancing coach productivity amid revenue adjustments.

Company News

  • Medifast Q3 Earnings on the Horizon: Key Insights for Investors

  • Why Is Weight Loss Different During Menopause? Common Myths Debunked

  • Medifast to Announce Financial Results for the Third Quarter Ended September 30, 2026

  • Best Momentum Stocks to Buy for October 14th

  • New Strong Buy Stocks for October 14th

  • 5 Questions People Ask When Every Weight Loss Approach Has Failed

  • What Actually Keeps Weight Off After a Weight Loss Program

  • Can Medifast's Better Client Retention Support Revenue Stabilization?

  • Why Do You Keep Gaining Weight Back After Losing It

  • What Are the 5 Signs of Poor Metabolic Health Adults May Overlook?

  • Why Weight Loss Plateaus Happen: 5 Metabolic Causes

  • Medifast's 3.0 Strategy Takes Shape: Can It Restore Profitable Growth?

  • Why Is Medifast (MED) Down 7.6% Since Last Earnings Report?

  • Ocius Technology to Add Sonar Systems to Bluebottle Fleet: NYSE Content Update

  • Medifast® Announces the Launch of the Medifast Metabolic Health Institute™

  • Can Medifast Capitalize on Rising GLP-1 Use With Metabolic Health?

  • All You Need to Know About Medifast (MED) Rating Upgrade to Buy

  • Great Lakes Advisors LLC Invests $548,000 in Medifast Inc $MED

  • Can Medifast's New Compensation Plan Accelerate Coach Growth?

  • Can Medifast's Coach Productivity Gains Help Revive Revenue Growth?